Riesgo cardiovascular en personas con colangitis biliar primaria, revisión de la literatura
Resumen
La colangitis biliar primaria (cbp) es una enfermedad autoinmune multifactorial (factores genéticos, disparadores ambientales como localización geográfica, fumar, microorganismos, xenobióticos). El objetivo de este estudio es describir los factores de riesgo relacionados con colangitis biliar primaria y cómo incide en el riesgo cardiovascular. Se realizó búsqueda bibliográfica en bases de datos de investigaciones originales, estudios de cohorte prospectivo y retrospectivo, estudios de casos y controles, revisiones sistemáticas y metanálisis, en los que se utilizaron palabras claves relacionadas. Se encontró relación entre las alteraciones en la cbp con el perfil lipídico, el cual aumentaba el estrés oxidativo, disfunción endotelial; sin embargo, los estudios que tratan de determinar el efecto de la hipercolesterolemia sobre el aumento del rcv en paciente con cbp han sido contradictorios. La esteatosis hepática está relacionada con aumento de los ecv y es común en las enfermedades hepáticas crónicas como hepatitis B y C crónicas y la enfermedad hepática grasa no alcohólica. La cbp puede tener manifestaciones extrahepáticas, dentro de estas las más prevalentes son las pulmonares como la enfermedad pulmonar intersticial y la hipertensión pulmonar.Este artículo presenta la relación entre la cbp con sus principales factores de riesgo y el desarrollo de enfermedades tanto hepáticas como extrahepáticas que aumenta el riesgo cardiovascular.
Descargas
Referencias bibliográficas
Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of cardiovascular events in patients with primary biliary cholangitis-systematic review. J Clin Transl Hepatol. 2018;6(2):119–26.
Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(2):93–110. Available from: http://dx.doi.org/10.1038/s41575-019-0226-7
Reshetnyak VI, Maev I V. Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. Biomedicines. [Internet]. 2022;10(12). Disponible en: https://doi.org/10.3390%2Fbiomedicines10123046
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis [Internet]. 2014;232(1):99–109. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2013.10.030
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 2007;194(2):293–9. Disponible en: https://doi.org/10.1016/j.atherosclerosis.2006.11.036
Yao S, Iwashita A, Yagi S, Watanabe H, Nishio T, Koyama Y, et al. Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report. Surg Case Reports [Internet]. 2022;8(1):1–7. Available from: https://doi.org/10.1186/s40792-022-01470-1
Park B, Islam S, Vemulapalli RC, Shreve ME. Primary biliary cholangitis presenting as acute ischemic stroke: A rare association. Clin Case Reports. [Internet]. 2020;8(2):274–7. Disponible en: https://doi.org/10.1002%2Fccr3.2590
Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L and Baldo V. Metabolic Syndrome Associated With Primary Biliary Cirrhosis. J Clin Gastroenterol. [Internet]. 2015;49(1):57–60.Disponible en: https://doi.org/10.1097/mcg.0000000000000029
Cazzagon N, Dal Lin C, Famoso G, Montisci R, Franceschet I, Floreani A, et al. Coronary flow reserve in patients with primary biliary cholangitis. Dig Liver Dis [Internet]. 2019;51(4):542–8. Disponible en:https://doi.org/10.1016/j.dld.2018.10.016
Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, et al. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal surveybased study. PLoS One. [Internet]. 2018;13(3):1–9. Disponible en: https://doi.org/10.1371/journal.pone.0194397
Maeda MH, Tsuji S, Shimizu J. Inflammator myopathies associated with anti-mitochondrial antibodies. Brain. [Internet]. 2012;135(6):1767–77. Disponible en: https://doi.org/10.1093/brain/aws106
Kenneth R. Feingold M. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. E, editor. South Dartmouth (MA): MDText.com, Inc.; 2000-.; 2021. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK305896/
Chen L, Chen XW, Huang X, Song BL, Wang Y, Wang Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. [Internet].62(11):1420–58. Disponible en: https://doi.org/10.1007/s11427-019-1563-3
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al.Pathophysiology of Atherosclerosis. Int J Mol Sci.[Internet]. 2022;23(6):1–38. Disponible en: https://doi.org/10.3390%2Fijms23063346
Sanuja Fernando, Bursill C, Nicholls S and Psaltis P. Pathophysiology of Atherosclerosis. Third Edit. Fitridge R, editor. Springer; 2020. 19–46 p. Disponible en: http://dx.doi.org/10.1007/978-3-030-43683-4_2
Loaeza-del Castillo AM, Gaytán-Santillán A, López-Tello A, Merit MVA, Milke-García M del P,Flores-Rodríguez J, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol [Internet]. 2019;18(6):879–82. Disponible en:https://doi.org/10.1016/j.aohep.2019.07.006
Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: Treatment, safety and efficacy. Frontline Gastroenterol. [Internet] 2019;10(4):401–8. Disponible en: https://doi.org/10.1136/flgastro-2018-101124
Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol [Internet]. 2021;21(1):1–8. Disponible en: https://doi.org/10.1186/s12876-021-01974-4
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. [Internet]. 2006;55(12):1795–800. Disponible en: https://doi.org/10.1136%2Fgut.2005.079814
Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. [Internet]. 2002;51(2):265–9. Disponible en: https://doi.org/10.1136/gut.51.2.265
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk? Hepatology. [Internet]. 1992;15(5):858–62.Disponible en: https://doi.org/10.1002/hep.1840150518
Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. [Internet]. 1997;32(1):77–83. Disponible en: https://doi.org/10.3109/00365529709025067
Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: A populationbased cohort study. Am J Gastroenterol. [Internet]. 2008;103(11):2784–8. Disponible en: https://doi.org/10.1111/j.1572-0241.2008.02092.x
Doycheva I, Chen C, Pan JJ, Levy C. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol. [Internet]. 2011;3(4):93–8. Disponible en: https://doi.org/10.4254%2Fwjh.v3.i4.93
Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: A nationwide follow-up study from Sweden. PLoS One. [Internet]. 2012;7(3):1–8. Disponible en: https://doi.org/10.1371/journal.pone.0033442
Wang C, Zhao P, Liu W. Brief Communication Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med [Internet]. 2014;7(9):2921–4. Available from: www.ijcem.com
Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, et al. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life. [Internet]. 2022;12(7). Disponible en: https://doi.org/10.3390%2Flife12071036
Cardinale V, Lleo A. Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. Dig Liver Dis [Internet]. 2019;51(4):549–50. Available from: https://doi.org/10.1016/j.dld.2018.11.017
Jones DEJ, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, et al. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol - Gastrointest Liver Physiol. [Internet]. 2010;298(5):764–73. Disponible en: https://doi.org/10.1152%2Fajpgi.00501.2009
Derechos de autor 2024 Revista Med
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
.png)
